The NHS's Pricey Problem: What's at Stake in the UK US Drug Deal The latest development in the contentious UK US drug pricing deal has campaign groups threatening to take the government to court over its plans to override the National Institute for Health and Care Excellence (Nice) assessments.
The proposed change, which could lead to higher prices for NHS patients, raises concerns about the UK's willingness to sacrifice patient care for short term economic gains.
Nice has been respected worldwide for its impartial assessment of drug treatments and recommendations on what the NHS should pay for them.